Piper Sandler Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences (NYSE:EW) had its price target hoisted by analysts at Piper Sandler from $70.00 to $73.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Piper Sandler’s price objective would suggest a potential downside of 2.88% from the stock’s current price.

EW has been the topic of a number of other research reports. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. The Goldman Sachs Group increased their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Royal Bank of Canada raised their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Evercore ISI lowered their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $79.71.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $75.17 on Wednesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $44.33 billion, a price-to-earnings ratio of 10.86, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The business has a 50 day simple moving average of $72.47 and a 200-day simple moving average of $69.32.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, equities research analysts expect that Edwards Lifesciences will post 2.56 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Abacus Planning Group Inc. boosted its position in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after acquiring an additional 140 shares in the last quarter. Bowman & Co S.C. increased its stake in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares during the period. Moors & Cabot Inc. raised its holdings in Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock worth $4,041,000 after purchasing an additional 152 shares during the last quarter. Pegasus Asset Management Inc. lifted its stake in shares of Edwards Lifesciences by 0.4% in the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after purchasing an additional 159 shares during the period. Finally, Mount Yale Investment Advisors LLC boosted its stake in Edwards Lifesciences by 1.9% during the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after acquiring an additional 162 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.